Lymphocyte-Activation Gene-3 Expression and Prognostic Value in Neoadjuvant-Treated Triple-Negative Breast Cancer

• DOI: 10.4048/jbc.2018.21.2.124
• Publication Date: 2018-06-22T02:09:54Z
• Authors: Yunxuan Wang; Tieying Dong; Qijia Xuan; Hong Zhao; Ling Qin; Qingyuan Zhang
• Keywords: Triple-negative breast cancer; Triple negative; Neoadjuvant Therapy; Tumor-infiltrating lymphocytes

In this study, we aimed to evaluate lymphocyte-activation gene-3 (LAG-3) expression and its prognostic value in neoadjuvant-treated triple-negative breast cancer (TNBC). LAG-3, programmed death-1 (PD-1), death ligand-1 (PD-L1), CD8+ tumor-infiltrating lymphocyte (TILs) levels were examined using immunohistochemistry 148 preand 114 post-neoadjuvant chemotherapy (NACT) specimens of human TNBC tissue. Correlations between clinicopathological features analyzed. Prognostic values for combined detection following NACT evaluated. pre-NACT specimens, LAG-3 showed a significant association with pathological complete response (pCR, p=0.038) was correlated PD-1 (p<0.001) PD-L1 (p=0.008). post-NACT high effects on nodal status (p=0.023) (p<0.001). The immune markers TILs significantly increased NACT. Multivariate analysis indicated that only (odds ratio [OR], 0.226; 95% confidence interval [CI], 0.079-0.644; p=0.005) quantities CD8+TILs (OR, 3.186; CI, 1.314-7.721; p=0.010) are independent predictors pCR. Nodal (hazard [HR], 2.666; 1.271-5.594; p=0.010), (HR, 0.313; 0.139-0.705; p=0.005), the LAG-3-high/PD-L1-high group 2.829; 1.050-7.623; p=0.040) provided patients sensitive predictive High residual tissues, especially combination PD-L1, associated poor prognosis.